PMN +29.8%, KNSA +25.1% Lead EPS Revision Gainers on Alzheimer's Data, Strong Earnings
Stocks with upward EPS estimate revisions delivered strong returns this week. PMN surged 29.8% after a safety readout for its Alzheimer's therapy, while KNSA gained 25.1% following Q2 earnings beat and raised guidance. NDLS jumped 22.5% on a massive 125 percentage point EPS growth revision.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| PMN | Healthcare | 2026-07-27 | N/A | +29.8% |
| KNSA | Healthcare | 2026-07-23 | N/A | +25.1% |
| NDLS | Consumer Cyclical | 2026-07-27 | +125.0pp | +22.5% |
| BZUN | Consumer Cyclical | 2026-07-24 | +2.2pp | +19.8% |
| ATEC | Healthcare | 2026-07-23 | N/A | +17.9% |
Why did PMN stock jump in July 2026?
PMN jumped 29.8% from $11.72 to $15.21 after analysts revised its forward EPS growth estimate to 27.1% on July 27.
The next day, positive interim safety and biomarker data from the PRECISE-AD Phase 1b trial for Alzheimer's drug PMN310 drove an additional 13% surge, confirming the revision's optimism. The blinded data showed no ARIA-E cases and favorable biomarker trends, reinforcing the therapy's potential.
PMN EPS revision history → · Screener snapshot from 2026-07-27 →
FAQ: PMN
Why did PMN stock jump in July 2026?
PMN jumped 29.8% after analysts raised its forward EPS growth estimate to 27.1% on July 27, followed by positive Alzheimer's trial data on July 28 that showed a strong safety profile and biomarker reductions.
What caused ProMIS Neurosciences' surge?
The surge was driven by an upward EPS revision and interim Phase 1b results for PMN310, which reported no ARIA-E cases and a 68.5% reduction in plasma pTau217 levels.
Is PMN a buy after the rally?
The rally reflects both improved earnings estimates and clinical progress, but investors should consider the early-stage nature of the Alzheimer's trial and the stock's volatility.
Why did KNSA stock jump in July 2026?
KNSA jumped 25.1% from $63.05 to $78.86 after analysts raised its forward EPS growth estimate to 39.7% on July 23.
The move accelerated on July 28 when Kiniksa reported Q2 revenue of $243.6 million (up 55% YoY), raised its 2026 ARCALYST sales guidance to $980-$995 million, and initiated the pivotal Phase 3 PASTORALE trial for KPL-387.
KNSA EPS revision history → · Screener snapshot from 2026-07-23 →
FAQ: KNSA
Why did KNSA stock jump in July 2026?
KNSA surged 25.1% after analysts raised its EPS growth estimate to 39.7% on July 23, and then Q2 results on July 28 beat expectations with record ARCALYST revenue and an increased full-year guidance.
What caused Kiniksa Pharmaceuticals' surge?
The surge was fueled by a strong EPS revision and a Q2 beat that showed 55% revenue growth, raised ARCALYST guidance, and positive Phase 2 data for its next drug KPL-387.
What is KNSA's EPS growth estimate?
KNSA's forward EPS growth estimate was raised to 39.7% following the revision detected on July 23.
Why did NDLS stock jump in July 2026?
NDLS jumped 22.5% from $14.25 to $17.46 after analysts doubled its forward EPS growth estimate from 184.1% to 309.1% on July 27.
This massive 125 percentage point revision—one of the largest in the sector—drove the rally without any specific news catalyst, signaling a sharp improvement in profitability expectations for the fast-casual chain.
NDLS EPS revision history → · Screener snapshot from 2026-07-27 →
FAQ: NDLS
Why did Noodles & Company stock jump in July 2026?
NDLS jumped 22.5% after analysts raised its forward EPS growth estimate from 184.1% to 309.1% on July 27, a 125 percentage point revision that implied a dramatic turnaround in earnings.
What caused Noodles & Company's surge?
The surge was caused solely by a massive upward EPS revision; no news or earnings release was reported in the detection window, indicating the market reacted purely to improved analyst expectations.
Is NDLS a buy after the rally?
The 125pp revision suggests strong momentum, but investors should monitor whether the company can deliver on those expectations without a specific operational catalyst.
Why did BZUN stock jump in July 2026?
BZUN jumped 19.8% from $2.48 to $2.97 after analysts raised its forward EPS growth estimate from 58.1% to 60.4% on July 24.
Although the revision was modest (2.2pp), it signaled improving profitability for the Chinese e-commerce services firm, possibly tied to cost optimization or a demand recovery in China, and no news was required to sustain the rally.
BZUN EPS revision history → · Screener snapshot from 2026-07-24 →
FAQ: BZUN
Why did Baozun stock jump in July 2026?
BZUN jumped 19.8% after analysts raised its forward EPS growth estimate to 60.4% on July 24, a revision that signaled brighter profitability prospects for the company.
What caused Baozun's surge?
The surge was driven by an upward EPS revision; no specific news was released, suggesting the market is betting on a recovery in China's e-commerce sector.
What is BZUN's EPS growth estimate?
BZUN's forward EPS growth estimate was revised from 58.1% to 60.4%, representing a 2.2 percentage point increase.
Why did ATEC stock jump in July 2026?
ATEC jumped 17.9% from $8.21 to $9.68 after analysts revised its forward EPS growth estimate to 83.2% on July 23.
The stock rallied without a news catalyst, reflecting growing confidence in Alphatec's path to profitability in the surgical robotics and orthopedics market, as the revision pointed to accelerating earnings expansion.
ATEC EPS revision history → · Screener snapshot from 2026-07-23 →
FAQ: ATEC
Why did Alphatec stock jump in July 2026?
ATEC jumped 17.9% after analysts revised its forward EPS growth estimate to 83.2% on July 23, a strong signal of improving profitability in the medical device sector.
What caused Alphatec Holdings' surge?
The surge was driven by a positive EPS revision with no accompanying news, indicating the market is rewarding the company's underlying earnings improvement.
What is ATEC's EPS growth estimate?
ATEC's forward EPS growth estimate stands at 83.2%, reflecting a significant upward revision detected on July 23.
These moves show the market rewarding companies with improving earnings estimates, particularly in healthcare and consumer cyclical sectors, even without major news catalysts for some names.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →